Group 1 - The company aims to enhance its sustainable profitability and optimize asset quality while considering investments in high-quality projects in the biopharmaceutical sector to cultivate new profit growth points [2] - The specific business situation will be based on the company's disclosed periodic reports and temporary announcements [2]

Core Viewpoint - The company plans to increase its investment in the subsidiary, Rail Chuang, by 74.98 million yuan, raising its ownership stake from 19.30% to 28.68%, which will not affect the scope of consolidated financial statements [1] Group 1: Investment Details - The capital increase will be classified as a related party transaction since the chairman of Rail Chuang is a director of the company [1] - After the capital increase, the company's stake in Rail Chuang will rise significantly, indicating a strategic move to enhance its investment portfolio [1] Group 2: Financial Performance of Rail Chuang - For the period from January to September 2025, Rail Chuang reported revenue of 17.64 million yuan and a net loss of 0.38 million yuan [1] - The financial performance highlights challenges faced by Rail Chuang, including long industrialization and commercialization cycles, as well as risks of not meeting expectations [1]

Core Viewpoint - Hengtong Co., Ltd. (600226) is actively engaged in the research, production, and sales of its main business areas, which include electrolytic copper foil, veterinary pharmaceuticals, feed additives, and cogeneration [1] Business Overview - The company has made investments and strategic arrangements around its main business, indicating a proactive approach to growth and diversification [1] - Hengtong and its wholly-owned subsidiaries have invested in and hold stakes in several companies, including Qingdao Yibang Bioengineering Co., Ltd. (17.45% stake), Hebei Shengxue Dacheng Pharmaceutical Co., Ltd. (49% stake), and Zhejiang Ikobike Animal Health Products Co., Ltd. (49% stake) [1]